Author:
Le Tourneau Christophe,Diéras Véronique,Tresca Patricia,Cacheux Wulfran,Paoletti Xavier
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference66 articles.
1. DiMasi JA, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25:209–216
2. Von Hoff DD (1998) There are no bad anticancer agents, only bad clinical trial designs—twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4:1079–1086
3. Ranson M, Hammond LA, Ferry D et al (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240–2250
4. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537
5. Shepherd FA, Rodrigues Pereira J et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献